Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine (NAC)

  • STATUS
    Recruiting
  • End date
    Dec 28, 2027
  • participants needed
    290
  • sponsor
    State University of New York - Upstate Medical University
Updated on 28 June 2022
corticosteroids
methotrexate
prednisone
hydroxychloroquine
azathioprine
lupus
immune tolerance
belimumab
antimalarials
Accepts healthy volunteers

Summary

Systemic lupus erythematosus (SLE) is a chronic inflammatory disease which often has debilitating and potentially life-threatening consequences. The cause of SLE is unknown and current therapies lack specificity and carry significant side-effects. We previously discovered the depletion of glutathione in lymphocytes of patients with SLE and associated this metabolic change with the elevation of the mitochondrial transmembrane potential.

This study will titrate to tolerance during an initial 3 month open label period and then subjects will be randomized to one of 2 arms.

It was determined by statistical analysis that each group must have 105 subjects. All subjects will be enrolled and evaluated for tolerance of NAC between dosages of 2.4 g/day and 4.8 g/day for 3 months. After A 3-month open-label dose-titration phase, SLE subjects will be randomized into 2 groups of 105 subjects either to continue the tolerated dosage of NAC or switched to equal number of placebo capsules. There will be up to seven study visits per SLE subject, including the screening and wash out visits. Visits 2-6 will be scheduled three months apart. The study will last 13 months with the wash-out visit. Each subject will donate approximately 100 ml of blood for biomarker studies at each visit. Healthy control subjects will donate blood at the same time. They will be matched to the SLE subjects by gender, age within 10 years, and ethnicity. Their blood will be used as reference for biomarker assays.

There is a consent form required to participate in the phase II study.

Description

Subjects will take NAC in a dose range of 2.4 g/day to 4.8 g/day which will be titrated to tolerance during an initial 3-month open label period. After the 3-month open label period, patients in each arm will continue taking equal numbers of capsules representing a dosage that has been titrated to tolerance. As an example, the patients tolerating 2.4 g/day, or 4 capsules containing 600 mg of NAC, after 3 months will be randomized to take 4 NAC or 4 placebo (2.4 g/day dextrose) capsules twice daily for the 9 subsequent months.

The primary outcome variable will be the response (yes/no) in the SLE Respinder Index or SRI at Month 12 (reduction ≥ 4 points in SELENA-SLEDAI score and therefore also called SRI-4; no new BILAG A organ domain score and no more than 1 new BILAG B organ domain score; and no worsening in Physician's Global Assessment (PGA) score) by ≥ 0.3 points versus baseline). A positive response will also require no treatment failure, defined as the need for non-protocol treatment, i.e., new or increased immunosuppressives or antimalarials; increased or parenteral corticosteroids; or premature discontinuation from study treatment. Corticosteroids can be tapered off at the investigator's discretion, based on disease activity. Four weeks after randomization, once tapered, corticosteroids can only be increased again to the dosage preceding the last taper step; any larger increase will be deemed a treatment failure. In addition, any increase in corticosteroid dosage during the last 3 months of the trial will result in declaration of treatment failure.

We will monitor tolerance and safety, and assess SLEDAI, BILAG, FAS, PROMIS, ASRS, prednisone use, liver and bone marrow function as secondary outcomes.

Details
Condition Systemic Lupus Erythematosus
Treatment Placebo, N-acetylcysteine
Clinical Study IdentifierNCT00775476
SponsorState University of New York - Upstate Medical University
Last Modified on28 June 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Age > 18 years old
SLE with ≥ 4 of eleven diagnostic criteria approved by the American College of
Rheumatology
Stable immunosuppressants (MMF ≤ 3 g/day, azathioprine ≤ 100 mg/day; methotrexate ≤ 15
mg/day) and/or antimalarials (hydroxychloroquine ≤ 400 mg/day) for 30 days prior to
screening; stable oral corticosteroids for 2 weeks prior to screening; ≤ 20 mg/day
prednisone or equivalent; stable belimumab for 90 days prior to screening
BILAG 2004 index level A disease activity in ≥ 1 organ/system except renal or central
nervous system or (ii) BILAG 2004 index level B disease activity in ≥ 2 organs/systems if
no level A disease activity is present and (iii) SLEDAI ≥ 6

Exclusion Criteria

Acute flare of SLE threatening vital organs and requiring intravenous
Pregnant or lactating
Moderately serious or serious comorbidities (e.g., diabetes mellitus, congestive heart
failure, chronic obstructive pulmonary disease, chronic renal insufficiency)
Patients receiving cyclophosphamide within 3 months
Active chronic infections (e.g., HIV, hepatitis B virus, hepatitis C virus, mycobacteria)
patient with oral steroid-dependent asthma
Infections requiring intravenous antibiotics within a month or oral antibiotics within two
weeks of screening; Patients taking (unwilling or unable to stop) NAC or other antioxidants
within 1 month of screening
Patients who participated in the pilot RCT or are taking daily acetaminophen (</= 1 g/day
PRN is allowed if documented)
Patients receiving rituximab within 12 months or other biologic therapy within five
half-lives
Patients receiving mTOR inhibitors (rapamycin/sirolimus, everolimus)
Patients enrolled in other interventional trials
Healthy subjects serve as controls for in vitro immunological studies
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note